The effects of aflatoxin exposure on Hepatitis B-vaccine induced immunity in Kenyan children.
Journal
Current problems in pediatric and adolescent health care
ISSN: 1538-3199
Titre abrégé: Curr Probl Pediatr Adolesc Health Care
Pays: United States
ID NLM: 101134613
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
20
5
2019
medline:
21
5
2020
entrez:
20
5
2019
Statut:
ppublish
Résumé
Globally, approximately three million children die each year from vaccine preventable infectious diseases mainly in developing countries. Despite the success of the expanded immunization program, not all infants and children around the world develop the same protective immune response to the same vaccine. A vaccine must induce a response over the basal immune response that may be driven by population-specific, environmental or socio-economic factors. Mycotoxins like aflatoxins are immune suppressants that are confirmed to interfere with both cell-mediated and acquired immunity. The mechanism of aflatoxin toxicity is through the binding of the bio-activated AFB We studied Hepatitis B surface antibodies [anti-HBs] levels to explore the immune modulation effects of dietary exposure to aflatoxins in children aged between one and fourteen years in Kenya. Hepatitis B vaccine was introduced for routine administration for Kenyan infants in November 2001. To assess the effects of aflatoxin on immunogenicity of childhood vaccines Aflatoxin B The mean ± SD of AFB Despite high coverage of routine immunization, less than half of the study population had developed immunity to HepB. Exposure to aflatoxin was high and weakly associated with low anti-HBs antibodies. These findings highlight a potentially significant role for environmental factors that may contribute to vaccine effectiveness warranting further research.
Sections du résumé
BACKGROUND
Globally, approximately three million children die each year from vaccine preventable infectious diseases mainly in developing countries. Despite the success of the expanded immunization program, not all infants and children around the world develop the same protective immune response to the same vaccine. A vaccine must induce a response over the basal immune response that may be driven by population-specific, environmental or socio-economic factors. Mycotoxins like aflatoxins are immune suppressants that are confirmed to interfere with both cell-mediated and acquired immunity. The mechanism of aflatoxin toxicity is through the binding of the bio-activated AFB
METHODS
We studied Hepatitis B surface antibodies [anti-HBs] levels to explore the immune modulation effects of dietary exposure to aflatoxins in children aged between one and fourteen years in Kenya. Hepatitis B vaccine was introduced for routine administration for Kenyan infants in November 2001. To assess the effects of aflatoxin on immunogenicity of childhood vaccines Aflatoxin B
RESULTS
The mean ± SD of AFB
CONCLUSION
Despite high coverage of routine immunization, less than half of the study population had developed immunity to HepB. Exposure to aflatoxin was high and weakly associated with low anti-HBs antibodies. These findings highlight a potentially significant role for environmental factors that may contribute to vaccine effectiveness warranting further research.
Identifiants
pubmed: 31103452
pii: S1538-5442(19)30039-2
doi: 10.1016/j.cppeds.2019.04.005
pmc: PMC7116700
mid: EMS113476
pii:
doi:
Substances chimiques
Aflatoxins
0
Albumins
0
Cytokines
0
Hepatitis B Antibodies
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-130Subventions
Organisme : Wellcome Trust
ID : 203077
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Vaccine. 2000 Apr 28;18(21):2295-306
pubmed: 10717350
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(7):1322-31
pubmed: 23767939
Neurosci Biobehav Rev. 2000 Aug;24(6):627-38
pubmed: 10940438
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(2):249-57
pubmed: 21623489
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Environ Health Perspect. 2003 Feb;111(2):217-20
pubmed: 12573908
J Infect Dis. 2016 Jul 1;214(1):1-3
pubmed: 26802140
Vaccine. 1999 Jun 4;17(20-21):2661-6
pubmed: 10418916
Soc Sci Med. 2015 Dec;146:104-10
pubmed: 26513119
Front Immunol. 2014 Sep 12;5:434
pubmed: 25309535
Pediatr Clin North Am. 2017 Aug;64(4):867-877
pubmed: 28734515
PLoS One. 2010 Nov 19;5(11):e14066
pubmed: 21124909
Annu Rev Food Sci Technol. 2014;5:351-72
pubmed: 24422587
Lancet. 1982 Jun 12;1(8285):1346-8
pubmed: 6123648
Clin Exp Allergy. 2009 Dec;39(12):1842-51
pubmed: 19735274
Matern Child Health J. 2015 Aug;19(8):1724-33
pubmed: 25636652
Future Microbiol. 2014;9(2):121-4
pubmed: 24571065
Semin Immunopathol. 2017 Nov;39(6):627-642
pubmed: 29124321
Gastroenterology. 1977 Mar;72(3):488-94
pubmed: 832797
Environ Int. 2013 Feb;52:51-65
pubmed: 23291098
Appl Environ Microbiol. 2007 Apr;73(8):2762-4
pubmed: 17308181
Int J Environ Res Public Health. 2017 Jun 13;14(6):
pubmed: 28608841
PLoS One. 2017 Feb 17;12(2):e0172124
pubmed: 28212415
Toxicol Sci. 2013 Sep;135(1):251-9
pubmed: 23761295
J Infect Dis. 1999 Feb;179(2):489-92
pubmed: 9878036
Int Immunol. 2005 Jun;17(6):807-14
pubmed: 15944194
J Infect Dis. 1999 Jun;179(6):1569-72
pubmed: 10228085
IARC Monogr Eval Carcinog Risks Hum. 2002;82:1-556
pubmed: 12687954
World J Gastroenterol. 2013 Mar 14;19(10):1508-12
pubmed: 23539499
Clin Microbiol Rev. 2001 Jul;14(3):476-88
pubmed: 11432809
Matern Child Nutr. 2016 May;12 Suppl 1:12-26
pubmed: 27187907
Eur J Cancer. 2012 Sep;48(14):2125-36
pubmed: 22405700
C R Acad Sci III. 1999 Nov;322(11):943-51
pubmed: 10646088
BMC Int Health Hum Rights. 2009 Oct 14;9 Suppl 1:S2
pubmed: 19828060
Nat Med. 2005 Apr;11(4 Suppl):S54-62
pubmed: 15812491
BMC Public Health. 2007 Aug 28;7:218
pubmed: 17725826
Adv Nutr. 2012 Jul 01;3(4):526-31
pubmed: 22797988
Blood. 2010 Mar 4;115(9):1678-89
pubmed: 19903895
Nat Rev Immunol. 2013 May;13(5):321-35
pubmed: 23618829
J Nutr. 2003 Jan;133(1):336S-340S
pubmed: 12514322
Am J Clin Nutr. 2004 Nov;80(5):1106-22
pubmed: 15531656
J Steroid Biochem. 1990 Feb;35(2):157-72
pubmed: 2407902
Toxicol Appl Pharmacol. 2008 Sep 1;231(2):142-9
pubmed: 18501398
J Appl Toxicol. 2014 Mar;34(3):241-9
pubmed: 23508487
Eur J Immunol. 2009 Jan;39(1):36-46
pubmed: 19089811
Crit Rev Toxicol. 2011 Oct;41(9):740-55
pubmed: 21711088